financetom
Business
financetom
/
Business
/
Teleflex Says FDA Clears AC3 Range Intra-Aortic Balloon Pump
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Teleflex Says FDA Clears AC3 Range Intra-Aortic Balloon Pump
Apr 1, 2025 6:08 AM

08:41 AM EDT, 04/01/2025 (MT Newswires) -- Teleflex ( TFX ) said Tuesday that the US Food and Drug Administration granted 510(k) clearance for its AC3 Range Intra-Aortic Balloon Pump to provide cardiac support for patients during transport.

The medical device maker said it will begin shipping the AC3 Range IABP to customers in Q2.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Percy H. Carter, Chief Scientific Officer, on June 05, 2024, sold 4,000 shares in Blueprint Medicines ( BPMC ) for $420,520. Following the Form 4 filing with the SEC, Carter has control over a total of 41,895 shares of the company, with 41,895 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1597264/000141588924015943/xslF345X03/form4-06072024_040602.xml ...
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Christopher Gibson, Director, Chief Executive Officer, on June 05, 2024, sold 100,000 shares in Recursion Pharmaceuticals ( RXRX ) for $871,000. Following the Form 4 filing with the SEC, Gibson has control over a total of 708,738 shares of the company, with 708,738 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000077/xslF345X03/wk-form4_1717790504.xml Price: 8.60, Change: +0.09,...
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Ronald M Shaich, Director, on June 05, 2024, sold 2,550,290 shares in Cava Group ( CAVA ) for $222,512,803. Following the Form 4 filing with the SEC, Shaich has control over a total of 7,149,899 shares of the company, with 5,000 shares held directly and 7,144,899 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1639438/000162828024027251/xslF345X03/wk-form4_1717790405.xml Price: 85.00,...
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Jun 7, 2024
04:06 PM EDT, 06/07/2024 (MT Newswires) -- Robert I Blum, Director, President & CEO, on June 04, 2024, sold 22,500 shares in Cytokinetics ( CYTK ) for $1,099,125. Following the Form 4 filing with the SEC, Blum has control over a total of 443,311 shares of the company, with 439,145 shares held directly and 4,166 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1061983/000112760224018143/xslF345X03/form4.xml...
Copyright 2023-2026 - www.financetom.com All Rights Reserved